This article has Open Peer Review reports available.
In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors
- Federica Barbieri†1, 2,
- Stefano Thellung†1, 2,
- Alessandra Ratto3,
- Elisa Carra4,
- Valeria Marini1,
- Carmen Fucile1,
- Adriana Bajetto1,
- Alessandra Pattarozzi1,
- Roberto Würth1,
- Monica Gatti1,
- Chiara Campanella3,
- Guendalina Vito3,
- Francesca Mattioli1,
- Aldo Pagano4, 5,
- Antonio Daga5,
- Angelo Ferrari3 and
- Tullio Florio1, 2Email author
© Barbieri et al.; licensee BioMed Central. 2015
Received: 14 July 2014
Accepted: 20 March 2015
Published: 7 April 2015
Cancer stem cells (CSCs) are considered the cell subpopulation responsible for breast cancer (BC) initiation, growth, and relapse. CSCs are identified as self-renewing and tumor-initiating cells, conferring resistance to chemo- and radio-therapy to several neoplasias. Nowadays, th (about 10mM)e pharmacological targeting of CSCs is considered an ineludible therapeutic goal. The antidiabetic drug metformin was reported to suppress in vitro and in vivo CSC survival in different tumors and, in particular, in BC preclinical models. However, few studies are available on primary CSC cultures derived from human postsurgical BC samples, likely because of the limited amount of tissue available after surgery. In this context, comparative oncology is acquiring a relevant role in cancer research, allowing the analysis of larger samples from spontaneous pet tumors that represent optimal models for human cancer.
Isolation of primary canine mammary carcinoma (CMC) cells and enrichment in stem-like cell was carried out from fresh tumor specimens by culturing cells in stem-permissive conditions. Phenotypic and functional characterization of CMC-derived stem cells was performed in vitro, by assessment of self-renewal, long-lasting proliferation, marker expression, and drug sensitivity, and in vivo, by tumorigenicity experiments. Corresponding cultures of differentiated CMC cells were used as internal reference. Metformin efficacy on CMC stem cell viability was analyzed both in vitro and in vivo.
We identified a subpopulation of CMC cells showing human breast CSC features, including expression of specific markers (i.e. CD44, CXCR4), growth as mammospheres, and tumor-initiation in mice. These cells show resistance to doxorubicin but were highly sensitive to metformin in vitro. Finally, in vivo metformin administration significantly impaired CMC growth in NOD-SCID mice, associated with a significant depletion of CSCs.
Similarly to the human counterpart, CMCs contain stem-like subpopulations representing, in a comparative oncology context, a valuable translational model for human BC, and, in particular, to predict the efficacy of antitumor drugs. Moreover, metformin represents a potential CSC-selective drug for BC, as effective (neo-)adjuvant therapy to eradicate CSC in mammary carcinomas of humans and animals.
KeywordsBreast cancer Cancer stem cells Metformin Comparative oncology
Breast cancer (BC) is the most common and fatal malignancy in women . Accumulating evidence supports the presence, within BC, of a subpopulation of tumor cells, named cancer stem cells (CSCs). These cells exhibit stem-like features, such as self-renewal, differentiation capacity, and are believed to represent the subpopulation responsible for the tumor-initiating activity and the resistance to antineoplastic agents [2,3]. In vivo, CSCs sustain tumor growth, reproducing the heterogeneity of the original tumor from which they are derived . According to the current carcinogenesis theory, BC development and recurrence is driven by CSCs , and these cells represent the main pharmacological target for tumor eradication. Breast CSCs were initially characterized from surgically removed human tumors, although their isolation was possible only in a small percentage of postsurgical specimens . However, since this first seminal study, most of the research on breast CSCs was carried out in established cancer cell lines [7,8], which were reported to contain putative CSC subpopulations. Conversely, only few studies were performed using cells isolated from tumor samples [9,10]. This limitation was likely a consequence of the CSC rarity within the tumor mass and the usually extremely small post-surgical specimens available for in vitro studies. A possible pitfall using cells expressing CSC signatures but isolated from continuous BC cell lines, is that they might include subsets of cells adapted to prolonged in vitro culture in the presence of high serum concentration that, overtaking the majority of the tumorigenic subpopulations, inadequately represent cancer cell heterogeneity. Moreover, due to genotypic and phenotypic alterations, these cells often show different drug responsivity from tumors in vivo [3,11].
The human BC cell subpopulation identified as CSCs is characterized by CD44+/CD24low/− phenotype, the ability to grow in vitro as mammospheres maintaining a constant percentage of stem cells, high tumorigenicity in vivo [6,9], developing serially transplantable tumors in immunodeficient mice , indicative of long-term self-renewal ability [13,14]. Moreover, several BC CSC features are also relevant to metastasis, such as high motility, invasiveness, and resistance to apoptosis and drug treatments.
Recently, comparative oncology emerged as a relevant tool for pharmacological development in human cancer research. Spontaneous pet tumors represent important pre-clinical models of human cancers retaining the heterogeneous nature of tumors and allowing the validation of treatment strategies that will result beneficial to both human and animal patients [15,16]. These tumors, which develop in immunocompetent animals, at odd with those experimentally induced in laboratory rodents, display genetic, histopathological and biological features similar to the human counterpart, as well as the metastatic pattern and the response to therapy . For example, spontaneous canine mammary carcinomas (CMCs) retain inter- and intra-tumor heterogeneity, as human cancer [18-20] but, due to the shorter life-span of dogs, they allow the evaluation of the natural course of the tumor and its pharmacological modulation after a shorter lag time than that required in human clinical trials. Thus, CMC is considered a reliable comparative model for human BC . CMC is the most common neoplasm of female dogs, representing 50-70% of all tumors , and multiple deregulated genes and signaling pathways (PI3K/AKT, KRAS, PTEN, Wnt-beta catenin, MAPK, etc.) identified as responsible for its development, nicely resemble those observed in humans . For example, the expression level of epidermal growth factor receptor (EGFR) in CMCs affects clinical prognosis ; HER-2 overexpression, occurring in about 20% of CMCs as in BC , or the loss of estrogen (ER) and progesterone (PR) receptors  are related to tumor progression. Moreover, triple-negative CMCs (lacking ER, PR and HER-2) show clinical-pathological characteristics associated with unfavorable prognosis, similarly to the triple-negative phenotype in women .
Because of the limited source of primary human BC tissues due to early diagnosis and multiple histopathological analysis required during and after surgery, and the lack of in vivo preclinical models that accurately reflect patients’ tumor biology, the study of pet spontaneous tumors may represent an innovative approach. However, this model is still underused and, in particular, studies on the role of CSCs in tumor development and treatment are lacking.
In veterinary research, putative CSCs have been identified in canine osteosarcoma, glioblastoma, acute myeloid leukemia, hepatocellular carcinoma [27-31], as well as in feline mammary carcinomas . CSC-like subpopulations were isolated and partially characterized from canine mammary cancer continuous cell lines [33-35], mainly relying on in vitro observations, such as spheroid formation, cell surface antigens and aldehyde dehydrogenase (ALDH) activity, whereas isolation of CSCs from spontaneous canine mammary tumors have been described only in few studies . Immunodetection of cells with CD44+/CD24− phenotype in canine mammary tumor tissues, similarly to human BC CSCs, has been also reported , and CD44 expression has been associated with proliferation of cultured canine cancer cells . Moreover, canine CSCs, isolated from the REM134 cell line, are resistant to common chemotherapeutic drugs and radiation, exhibiting epithelial-mesenchymal transition (EMT) phenotype .
Metformin is the first-line hypoglycemizing agent used for the treatment of type 2 diabetes (T2D) due to its efficacy and safety profile . Epidemiological studies reported that metformin-treated T2D patients show reduced cancer incidence and mortality; furthermore metformin therapy seems to improve the clinical outcome of diabetic patients with cancer and to exert a protective anticancer effect in non-diabetic patients [40,41]. Thus metformin’s antitumor properties are currently tested in several clinical trials, mainly focusing on BC [42,43]. Preclinical in vivo studies reported that metformin reduces growth of BC xenografts in mice [44,45], and directly inhibits the proliferation of several BC [46,47] and other tumor  continuous cell lines, mainly interfering with CSC proliferation. However, in all these studies the effects of metformin, alone or in combination with doxorubicin or trastuzumab, were mainly evaluated in CSC-like derived from established lines [49-51].
Thus, the evidence of metformin activity in human BC CSCs is still limited, and a comparative approach studying CSCs from spontaneous dog tumors presents several advantages, including the retention of intra-tumor cell heterogeneity, an extremely relevant issue to identify pharmacological approaches with higher predictive validity when translated from preclinical to clinical setting. Moreover, since these tumors are often not treated before surgery, comparative oncology provides the unique opportunity in a preclinical model to map the nascent BC biology, without modifications induced by therapy pressure. Since CSCs are generally highly resistant to chemotherapy, drugs that successfully target this subpopulation may represent an effective therapeutic approach, and the analysis of efficacy on CMC may pave the way to the identification of clinically useful compounds in humans.
The aim of this study was to establish cell cultures enriched in CSCs from spontaneous CMCs, in order to provide a cellular model that may better reflect BC heterogeneity, pathogenesis and drug responses. Moreover, we tested the effects of metformin on CSCs isolated and characterized from spontaneous CMCs, providing evidence that these cells are highly responsive to in vitro and in vivo metformin treatment.
Canine mammary carcinoma tissues
Sixteen CMC samples were collected after surgical resection from the local network of free-lance veterinary practitioners (Genova, Italy), as described . All histopathological diagnoses were reviewed and assessed according to the WHO International Histological Classification of Mammary Tumors of the Dog and Cat , and tumor grade was assigned .
Immunohistochemistry (IHC) was as described previously . Antibodies used were as follows: anti-EGFR (rabbit polyclonal; Cell Signaling Technology), anti-ER-α clone 1D5, anti-CD44, clone DF1485 and anti-Ki-67, clone MIB-1, (mouse monoclonal, Dako, Glostrup, Denmark) and anti-CD24 (goat polyclonal; SantaCruz Biothechnology). All these antibodies are directed against human epitopes but cross-react with the canine counterpart, as described [55-57]. Briefly, paraffin sections were deparaffinized and rehydrated, antigen unmasking was performed using citrate-antigen retrieval and Real Envision Detection System Peroxidase/DAB+, mouse/rabbit (Dako) was used for the detection according to the manufacturer's instruction. Counterstaining with haematoxylin concluded the processing. Images were captured using a Nikon Coolscope microscope. For CD44, ER-α and EGFR expression, both the intensity of immunoreaction and the percentage of positive cells were evaluated, and a score ranging from 0 to 3 was assigned (0 = negative, 1 = low positivity, 2 = positivity, 3 = high positivity). Ki-67 labelling index (Ki-67 LI) was evaluated, using anti-Ki-67 antibody, as the percentage of positive cell out of at least 1,000 neoplastic cells (Ki-67 LI: 1 = <10%, 2 = 10-50%, 3= > 50%), in 10 randomly selected microscopic fields. For each staining, a positive control was included (human breast cancer tissues), as well as a negative control, without the primary antibody or with rabbit/mouse IgG. Mitotic index (MI), as an indirect measure of cell proliferation, was evaluated as the number of mitotic figures per 10 high-power fields (HPF). Mitotic figures were counted in areas selected on the basis of the presence of good cellularity and high density of mitotic figures. Counting and semi-quantitative estimate of percentage of positive cells of IHC was evaluated and independently scored by two pathologists (A.R. and C.C.).
After surgery, tumor tissues were immediately processed for isolation of CSCs . Tumor were finely minced and incubated in trypsin/collagenase for 20 min with agitation at 37°C, vigorously pipetted and cells passed through a 70 μm strainer (BD Biosciences, Milano, Italy) to obtain individual cells then plated in DMEM/Ham's F12 (1:1) medium, penicillin/streptomycin (100 U/ml), and glutamine 2 mM supplemented with 10% fetal bovine serum (FBS) (all from Lonza, Milano, Italy) or in a stem-cell permissive medium: (DMEM/Ham's F12 (1:1) without FBS, additioned with EGF (20 ng/ml), bFGF (10 ng/ml) both from Milteny Biotec (Bologna, Italy), 0.4% BSA (w/v, Sigma-Aldrich, Milano, Italy), and insulin (5 μg/ml, Sigma-Aldrich) to ensure stemness maintenance [9,32]. To induce differentiation, sphere colonies grown in stem-permissive medium were collected, dissociated into single cells, and shifted to complete FBS-containing medium (without growth factors) and cultured for at least 2 weeks .
Cell immunophenotyping by immunofluorescence
To characterize CMC cells and visualize the expression of specific markers, immunocytofluorescence (IF) was performed . Briefly, stem (mammospheres) and differentiated cells grown on coverslips were fixed in 4% paraformaldehyde, blocked in normal goat serum (Sigma-Aldrich) and the following antibodies were applied for 1 h at r.t.: CD44 (Cell Signaling Technology, Danvers, MA, USA), epidermal growth factor receptor (EGFR, Cell Signaling Technology), ER-α and pan-cytokeratin (pan-CK) (Dako). Secondary fluorescent antibodies, Alexa 488- and Alexa 568-conjugated goat rabbit/mouse-specific (Molecular Probes, Life Technologies, Monza, Italy), were added for 1 h at r.t. Nuclei were counterstained with 4',6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich). Negative controls were included in the experiments by omitting primary antibodies. Images were captured by confocal laser scanning microscope (Bio-Rad MRC 1024 ES).
Cytotoxic effects were determined using the MTT [3-(4,5-dimethylthizol-2-yl)-2,5-diphenyltetrazolium bromide] (Sigma-Aldrich) reduction assay . Briefly, viable cells (3x105) were plated into 48-well plates and incubated overnight prior to exposure to increasing concentrations of metformin (0.1-100 mM) and DOX (0.01-5 μM) in the presence or absence of verapamil (10 μM). Cells were incubated with MTT solution 0.25 mg/ml for 2 h at 37°C, medium was removed and stain was solubilized in DMSO; absorbance was measured spectrophotometrically at 570 nm. Dose–response curves were generated and IC50 values were calculated using nonlinear regression curve fit analysis by Graph Pad Prism 5.2 (GraphPad Software, San Diego CA, USA).
Stemness of CMC CSCs was tested measuring the colony-forming ability of individual cultures . Cells were seeded in 96-well plates, at <1 alive cell/well concentration; medium was changed twice a week. Plating accuracy was monitored under light transmitted microscope to confirm the presence of a single cell/well and exclude wells with dead or multiple cells. The number of wells that contained colonies was scored weekly up to 4 weeks.
Doxorubicin uptake and intracellular distribution assay
The natural fluorescence of doxorubicin (DOX, Sigma-Aldrich) allows it to be localized by fluorescence microscopy in vitro . CMC cells were seeded in 35 mm glass bottom dishes and allowed to growth o.n., then cells were exposed to 1 μM DOX for 20 h, in the presence or absence of 10 μM verapamil (Sigma-Aldrich). Cells were washed to remove non-associated drug and counterstained with the lipophilic membrane stain Vybrant DiO cell-labeling solution (Molecular Probes, Life Technologies, Monza, Italy). Images were captured by a DM2500 microscope equipped with a DFC350FX digital camera (Leica Microsystems, Wetzlar, Germany).
In vivo xenograft studies
Female non-obese diabetic severe combined immunodeficient (NOD-SCID) mice (6–8 weeks old; Charles River, Calco MI, Italy) were used to evaluate tumorigenicity of CMC cultures [32,60]. Animals, housed in pathogen-free conditions, were handled in agreement with Italian regulations for the protection of animals used for scientific purposes and guidelines of the Ethical Committee for Animal Experimentation of the IRCCS-AOU San Martino-IST (Genova, Italy). Viable cells (4x105) were collected by centrifugation, resuspended in matrigel (BD Biosciences) and pseudo-orthotopically injected in the subcutaneous fat pad. Mice were inspected weekly for tumor appearance by visual observation and palpation, thereafter were monitored for any discomfort and weighed until sacrifice. Tumor tissues were collected and dissociated to single cells as described above and after spheroid formation, cells were re-injected into new recipient mice to verify tumor-forming ability and incidence. The remaining tumor, fixed in 10% buffered formalin and embedded in paraffin was used for hematoxylin and eosin (H&E) histological evaluation. Treatments were started 7 days after inoculation of cells, in mice randomly allocated to groups receiving metformin or vehicle and continued for the next 6 months until the mice were killed. Metformin hydrochloride (Sigma-Aldrich) was dissolved in drinking water to attain the dosage of 360 mg/kg/die (see dose justification in Discussion). The water was changed every other day and measured for water intake. No toxicity signs were observed in the treated animals. Excised tumors were weighed, and portions were cultured or fixed for further studies.
Plasma metformin measurement by high-performance liquid chromatography (HPLC)
Plasma concentrations of metformin in treated mice were determined by validated HPLC assay . Mice blood samples (~0.3 ml) were taken under anesthesia by retro-orbital sinus bleeding, collected into heparinized tubes and centrifuged at 3000 x g. Metformin hydrochloride was used for calibration standards and as reference substance. Mouse plasma and standards were extracted with acetonitrile (0.5 ml) and reconstituted with water. An aliquot of each extracted sample (50 μl) was injected onto a Kontron HPLC system (Kontron Instruments, Munich, Germany), connected to an oven L-7350 column (Merck Darmstadt, Germany) and eluted with a mobile phase consisting of 20 mM K2HPO4 and acetonitrile (97:3 v/v) at a flow rate of 1 ml/min at 18°C. The UV detector (Kontron Instruments) was set at 236 nm (ABS 0.1, RT 0.1); the run lasted for 10 min. Results analysis was performed using the signal integration software KromaSystem 2000 (BIO-TEK Instruments Milano, Italy). The calibration curves of peak areas vs. concentrations of metformin were linear giving a correlation coefficient r2 = 0.999.
All quantitative data were collected from experiments performed in triplicate, and expressed as mean ± s.e.m. Statistical analyses were performed using t-test (unpaired, two-tailed) or one-way ANOVA with Dunnett’s or Tukey’s post-tests, using GraphPad Prism 5.2 (GraphPad software). Differences were considered significant for p < 0.05.
Clinical and histopathological characterization of CMCs
Clinical data and histopathology of canine mammary carcinomas
10 yrs. (range 6–14)
CD44 expression, a potential CSC marker, as determined in human BC CSC (phenotype CD44+/CD24-/low), was detected in scattered cells (score 1) in the 31% of the cases, or in limited tumor regions (score 2) in 15%, while 54% of tumors were negative. However, as previously reported , CD44 is likely underestimated by random IHC sampling, due to the non-homogeneous expression within tissues, the predicted rarity of these cells, their potential localization in stem cell niches and the lack of analysis of serial sections of the samples. The expression of CD24 was checked in our series of CMC tissues but no stained cells were detected, accordingly to previous observations [32,37].
Isolation and in vitro expansion of cancer stem-like cells from CMC specimens
Phenotypic characteristics of canine mammary carcinoma cells cultured in stem-permissive medium
To verify whether primary CMC cultures grown in stem cell-permissive medium are indeed enriched in CSCs, we characterized the phenotype of these cells by IF (Figure 2c, upper panels). All stem-like cultures exhibited pan-cytokeratin expression, consistent with their epithelial origin. As self-renewal of human and animal mammary cancer stem cells involves a diverse network of regulatory mechanisms, including the signaling pathways of EGFR, CXCL12/CXCR4 and ER-alpha, we analysed whether these proteins are expressed in CMC cultures.
We observed a marked positivity for EGFR within spheres and single cells growing under stem-permissive/serum-free conditions indicating that EGFR immunopositivity observed in tissue sections was retained after CSC enrichment in vitro. CXCR4 was also expressed in CSC cultures showing predominant membrane localization. Conversely, the expression of ER-α was not detected in all the cells of the analyzed spheroids, and 30% of them were completely negative, in agreement with IHC analysis (see Figure 1). Importantly, the expression of CD44, previously reported as signature of human breast CSCs , was detected in all cultures, providing evidence for enrichment in stem-like cells and validating their identification in corresponding CMC tissues (Figure 2c). Differentiated cells (shifted to serum-containing medium) conserved similar expression profiles of all the markers, with the remarkable exception of CD44, which was undetectable after differentiation (Figure 2c).
CMC stem cells are tumorigenic in vivo
Collectively these data confirm the tumor-initiating capacity of isolated CMC CSCs, and their ability to recapitulate the phenotype of the original tumor in vivo.
CMC stem cells are resistant to doxorubicin: reversal of the resistance by verapamil
Human BCs develop numerous mechanisms of resistance to chemotherapeutic drugs, allowing them to survive conventional therapies and to drive tumor recurrence and metastasis. CSCs are believed to represent the main source of drug-resistant cells .
One of the most common mechanism of resistance to DOX, representing also a key feature of CSC subpopulation, is the overexpression of ATP-binding cassette transporters (ABCB1, ABCG2, and ABCC1) whose activity leads to cell extrusion of cytotoxic drugs.
To gain further insights into the role of ABC pumps in drug resistance, we assessed the intracellular distribution of DOX autofluorescence in CMC CSCs. We expected that high activity of multidrug resistance transporters would change the pattern of DOX localization and, specifically, decrease its nuclear accumulation. As shown in Figure 4b, after 24 h of treatment, DOX either was extruded from the majority of the CSCs or, when entered cells, it was pumped out from the nucleus accumulating in perinuclear/cytoplasmic structures, as evidenced by the merge of vital cell dye DiO (green) and DOX (red) fluorescences, resulting in colocalization (yellow) (Figure 4b, left panel). Inhibition of ABCB1 pump function, by the calcium antagonist verapamil (10 μM), prevented DOX exclusion, resulting in its accumulation within the nucleus of all the cells (Figure 4b, right panel), a similar pattern to that observed in DOX-sensitive differentiated cells (data not shown). These results, suggesting ABCB1 involvement in CSC DOX resistance likely due to reduced access to nuclear targets, were confirmed by MTT experiments. CMC CSCs treated with DOX plus verapamil for 48 h acquired a significant responsivity to the cytotoxic drug (p = 0.025 vs. DOX alone, ANOVA) (Figure 4c), reaching a mean IC50 of 0.45 μM, a value that was almost superimposable to that observed in differentiated CMC cells (Figure 4d). Verapamil had no significant effects on the subcellular distribution or accumulation of DOX in differentiated cells that however showed a nuclear localization of the drug also in the absence of verapamil (data not shown).
Metformin inhibits CMC stem-like cell viability in vitro
Differentiated cell cultures were obtained in parallel with stem-like cells from 13/16 tumors. Differently from what reported in BC cell lines in which metformin was highly selective for the CSC component , metformin also affected viability of CMC cells grown in FBS-containing medium, at concentrations higher than 10 mM (Figure 5c), showing a higher mean IC50 value, but not statistically different from that obtained in the CSCs isolated from the same tumors (24.5 mM vs. 17.8 mM). However, comparing viability curves of both culture conditions, we found that CSCs display a significantly higher reduction of viability than differentiated cultures at all the tested concentrations, with the exception of the lowest one (0.1μM; Figure 5c), suggesting that metformin actually targets with higher efficacy CSC-like cells, while doxorubicin more efficiently blocks differentiated cell proliferation.
Metformin impairs the growth of CMC stem-like cell in vivo
Finally, to define the impact of in vivo metformin treatment on CSC viability, we analyzed the clonogenic activity of individual CMC cells in ex vivo experiments, as a CSC-based in vitro index of in vivo tumorigenicity. Cells, derived from treated and control tumors, grown in stem-permissive medium, were plated as single cells and allowed to give origin to clones for up to 30 days. About 13% of the cells derived from untreated tumors retained clonogenic activity, a percentage compatible with the CSC levels within the tumor mass, while only 2% of the cells from metformin-treated xenografts retained this stem-defining feature. These data clearly suggest that in vivo metformin treatment powerfully affect the survival of CSCs. In addition, we observed that CMC cultures derived from untreated and chronically metformin-treated xenografts, grown in stem cell-permissive conditions, were similarly sensitive to the antiproliferative activity of metformin (IC50, 22 and 26.6 mM, respectively) showing superimposable dose–response curves (p = 0.3513; data not shown), providing evidence that desensitization of the antiproliferative mechanisms activated by metformin does not arise during prolonged in vivo treatment.
The hierarchical model of carcinogenesis implies that only a small subset of tumor cells, named CSCs or tumor-initiating cells, drives tumor development and progression, determining drug responsiveness. Conversely, differentiated tumor cells, incapable of long-term self-renewal but representing the majority of the cells within hematologic and solid cancers, are not tumorigenic. Although most studies addressing this issue relied on established cancer cell lines rather than primary cultures, it is now clearly evident that putative CSC identification and usefulness is strictly coupled with powerful and systematic in vitro isolation and in vivo transplant of CSCs derived from fresh tumor tissues .
In the present study, we isolated and characterized CSCs from CMC surgical tissues, by selection of primary CMC cultures in stem cell permissive, serum-free medium for several passages in vitro. CMC-derived stem cell-like spheroids express CD44, as well as other BC related proteins, such as EGFR and CXCR4, and showed high resistance to DOX when compared to the corresponding CMC differentiated cells. Xenografts in NOD/SCID mice demonstrated that CMC CSCs derived from mammosphere disaggregation, successfully initiate tumor formation.
Breast cancer remains a major clinical challenge with high mortality both in humans and companion animals [1,25]. Advancement in understanding tumor biology and public awareness campaigns led, in most cases, to early BC diagnosis and neo-adjuvant treatments were developed in women. While the better clinical management significantly improved the overall prognosis of BC patients, only small fragments of fresh tissues, frequently already exposed to intensive cytotoxic therapy, are available from excised human tumors for experimental purposes, also because large amounts are required for intra- and post-surgery histopathological analyses. On these premises, a major strength of our study is the use of spontaneous dog tumors as a source of biological material necessary to isolate mammary CSCs. Indeed, to improve the knowledge of in vitro and in vivo biological features of CSCs and their drug responses, allowing the translation of preclinical findings into effective human clinical trials, cell models that faithfully mimic BC cell heterogeneity are an absolute requirement. Spontaneous tumors of companion animals, such as CMC, are rather frequent in the clinical veterinary practice  and thus may provide a unique opportunity as a model for human cancer translational research . In contrast to experimental tumor models in mice, CMCs develop naturally, reproducing the same environmental and genetic aetiology as occurs in humans, grow in immunocompetent organisms  and share strong clinical (e.g. hormonal dependence, age of onset, histological appearance, prognostic factors, course of the disease) and molecular (e.g. tumor genetics, overexpression of steroid receptors, proliferation markers, EGF, p53 mutations, metalloproteinases, cyclooxygenases) similarities to human BC [20,22].
Additionally, human and canine mammary tumors show similar responses to conventional anticancer agents and, more importantly, both display inter/intra-patient tumor cell heterogeneity . The enrichment in CSCs has been largely demonstrated in established human and canine mammary cancer cell lines . Here, we reinforce the hypothesis of the stem cell basis for mammary tumors, achieving isolation of such a population from surgical samples. Features of CSCs include: (i) self-renewal capacity, (ii) stem marker expression, (iii) ability to reproduce the original tumor after xenografting, and (iv) chemo-resistance. Therefore, we verified these prerequisites in CSCs derived from CMCs. Cell surface marker CD44 , and the expression of the enzyme aldehyde dehydrogenase (ALDH), partially overlapping within this subpopulation , were assumed as criteria for CSC-enrichment and stem signatures in human BC, correlating to the tumor-initiating ability. However, it is currently debated whether these markers univocally identify CSCs in all BCs [70,71]. Breast CSC plasticity induced by tumor microenvironment, which allows these cells to undergo reversible EMT, may influence distinct marker profiles . Nevertheless, CD44 was identified as major target using CD44 antibodies  or inducing CD44 down-regulation [74,75], to inhibit CSC proliferation and migration and overcome drug resistance.
In dogs, limited studies on mammary CSCs are available, thus their phenotyping is mainly derived from commonly employed human markers [33,36], reproducing similar controversies: spheres from primary tumors show the expression of CD49f (integrin α6) and CD29  while spheres derived from canine cell lines express CD44 and CD133 and/or Sox2 and Oct4 . Moreover, CD44 was associated to proliferative activity of cultured canine cancer cells [38,71]. CMC cultures, analysed after in vitro enrichment in stem-like cells, display CD44 expression in a high number of cells, while, in the tumor of origin, CD44+ cells are confined in randomly spotted tissue areas, as described for human samples , explaining, as previously discussed, the apparent high percentage of CD44 negative tumors. However, although this is a non-defining criterion for CSC identification  and we did not select CMC CSCs on the basis of markers’ expression, we observed a depletion/decrease of CD44+ cells upon CMC CSC differentiation (shifting cell cultures in serum-containing medium), confirming that this marker labels some CSC-like populations in culture. In addition, we analysed the expression of genes associated, in human and pet mammary cancers, with stem/progenitor cell survival, self-renewal and tumor aggressiveness, such as EGFR, ER-α and CXCR4 [54,77,78]. Similarly to the original tumors, CMC mammospheres quite homogenously express EGFR confirming its relevance in mammary cancer biology, and CXCR4, whose signalling regulates BC stem cell activities and metastatic potential [54,79]. Conversely, ER-α positivity was less commonly detected in isolated CMC stem-like cells and in tumor sections. The pattern of expression of these proteins did not change in the corresponding differentiated CMC cultures, showing that both the bulk of CMC cells and CSC-enriched cultures retain in vitro the same distinctive factors, as master regulators of tumor formation and growth. Thus, CSC cultures isolated from CMCs reproduce the tissue heterogeneity, covering different histopathological types and maintaining in culture the phenotype observed in vivo.
CSC biomarker expression  and the ability to growth in serum-free medium as non-adherent spheroids  are variably identified features in human and canine mammary tumors, reflecting intra- and inter-tumor heterogeneity but do not systematically define CSCs . Thus, functional validation, by means of in vivo tumorigenicity experiments, is actually the more reliable tool to corroborate the definition of cell populations as CSCs (tumor-initiating cells). We demonstrate that CSCs isolated from CMC retain tumor-initiating activity, by serial transplantation in NOD-SCID mice (CSCs were xenografted, recovered and re-transplanted to form new tumors in new recipient mice) achieving about 100% of take rate after both 1st and 2nd injection, reforming the heterogeneous population of CMC cells within the xenografts. Another biological property generally ascribed to CSCs is drug resistance, as they more efficiently survive therapy than differentiated cancer cells. Indeed, the major challenge in BC treatment is the targeting of CSCs usually refractory to conventional drugs both in humans and in dogs . This underlines the need of novel preclinical models to test drug effects on CSC biological features such as increased drug-efflux and DNA repair ability, and resistance to apoptosis, that contribute to drug resistance. In fact, using these mechanisms CSCs survive therapies contributing to recurrence and progression, after the initial remission caused by the differentiated tumor cell death . Drug-resistance of CMC CSCs is therefore similar to that observed in human BC stem cells, whose content within the tumor mass is increased by chemotherapy , and in CSCs isolated from a CMC cell line . Therefore, although cytotoxic treatments reduce the bulk of the tumor, they may not affect the most important target: the CSCs. In this study we developed a preclinical model reproducing this in vivo condition. CMC CSCs survived DOX treatment, at odd of differentiated cultures isolated from the same tumors, likely due to transporters that pump out the drug from the nuclei or outside the cells.
The need of drugs effectively targeting CSCs inspired new approaches for anti-cancer drug discovery and in particular the so-called “drug repositioning”. It was reported that the biguanide metformin specifically inhibits self-renewal and proliferation of CSC from several tumors [66,84,85], including BC [49,51,86,87]. Starting from early evidence using different biguanides [88-90], the antitumor potential of metformin is now well-established [65,91]. Epidemiological studies showed that diabetic cancer patients may benefit of metformin treatment and, on these bases, several clinical trials are ongoing . Recently, the inhibition of chloride intracellular channel 1 (CLIC1) activity was identified as a specific molecular mechanism by which metformin affects only CSC viability, sparing normal stem cells , making this molecule particularly interesting as novel anticancer drug. We show that canine CSCs are not sensitive to DOX cytotoxicity, but highly responsive to metformin in vitro, while differentiated tumor cells are only partially affected by metformin, although highly responsive to DOX. These data confirm that combined treatment with metformin and conventional cytotoxic drugs may provide a therapeutic advantage. In fact, while metformin is clearly preferentially active on CSCs, a successful therapy will require targeting of both undifferentiated CSCs and differentiated non-CSCs , since the reverse transition of non-CSCs into CSC subpopulation was also reported . Mean metformin IC50 values obtained in our experiments is about 10 mM, ranging from 0.40 to 31 mM in cells from different tumors, evidencing significant variability in metformin activity among individual dog-derived cells, as expected for the inter-patient tumor heterogeneity, although we remark that viability of CSCs from all 13 CMCs analyzed was impaired. These IC50 values are in line, and in some cases lower, with those of most of the previous studies reporting antitumor activity of metformin (range 1–30 mM) [44,87,96,97]. However, metformin concentrations used in vitro, exceeding those achieved in vivo in T2D patients (10–30 μM range) , are still a debating issue, due to the concern whether these in vitro data might be relevant for translation to clinics . We acknowledge that the concentrations used are higher than metformin steady state plasma levels in T2D patients, however, the discrepancy between clinical and in vitro conditions could be less significant considering the following factors: (a) metformin concentrations in tissues are several-fold higher than those in blood because of tissue accumulation , thus actual intra-tumor concentrations should compare with in vitro results; (b) medium supplements, required to maintain tumor cell proliferation in culture (i.e. high concentrations of glutamine and glucose), reduce cell sensitivity to metformin [4,100,101]; (c) tumors often show increased cationic transporters compared their normal counterparts  further favoring tissue accumulation, (d) longer exposure of cell cultures to metformin (15–18 days) shift metformin-antitumor effect to a lower threshold . In fact, it was reported that in human glioblastoma CSCs, short-term experiments (24-72 h, as here reported) show metformin anti-proliferative activity in the mM range [44,93,102], but increasing drug exposure to 15 days metformin efficacy was evident already at 10 μM concentration . This latter point might justify higher IC50 in in vitro studies, supporting time-dependent mechanisms that significantly differ between in vitro and in vivo experimental conditions. This hypothesis was indeed supported by our demonstration that prolonged metformin treatment of CMC xenografts resulted in reduced tumor size and growth arrest and depletion of CSC content, for much lower blood concentrations (about 40 μM) than required in vitro (about 10mM). The plasma levels obtained treating mice with metformin dissolved in drinking water to attain the dosage of 360 mg/kg body weight/day, which is comparable to therapeutic doses used for T2D as translated to humans (human equivalent dose : corresponding to ~1,750 mg/day in an average-sized person of 60 kg), are therefore lower than the maximum recommended dose in humans (http://www.fda.gov/ohrms/dockets/dailys/02/May02/053102/800471e6.pdf).
Thus, in vivo dosing that induces a highly significant reduction of tumor growth is within human therapeutic range, even if the high safety profile and negligible side-effects of metformin could allow experimental doses over pharmacological concentrations. In very recent phase II and III clinical trials, non-diabetic women with BC received metformin at high dose (2 g/day) as adjuvant therapy [43,92], demonstrating that higher blood concentrations can be safely achieved.
Notably, our study demonstrates that the clonogenic potential of cells surviving long-term in vivo exposure to metformin, was markedly reduced as compared to untreated controls, indirectly confirming that metformin preferentially kills CSCs. Moreover, desensitization induced by prolonged exposure to metformin does not occur in CMC CSCs after prolonged in vivo treatment, since metformin still exhibits a strong and consistent antiproliferative action in vitro on cells derived ex vivo from both treated and untreated mice tumors. Above observations support metformin as an attractive agent for chemoprevention and use of low-dose for long period in combination with cytotoxic agents like DOX to kill both CSCs and the bulk of differentiated cancer cells.
CSC-like subpopulation can be isolated from spontaneous canine mammary carcinomas, strongly highlighting the relevance of the comparative oncology model. Our data support CMC stem-like cells as a powerful model to provide information closer-to-primary cellular models for the identification of novel CSC targeting agents and the definition of biological behavior of stem-like cells in human BC. The demonstration of significant antitumor efficacy of metformin acting on CSC proliferative potential, along with the well-known safety profile support the ongoing evaluation of metformin in the clinical neo-adjuvant setting, although additional studies evaluating metformin effects in conjunction with standard treatments are needed to further focus the potential clinical benefits of this drug in BC. Companion animals could be investigated for possible translation to veterinary and human medicine, which may strengthen the use of naturally occurring CMC in dogs in comparative oncology trials.
This work was supported by grants from Italian Association for Cancer Research (AIRC) (2012) and Ricerca Corrente IZS-PLV (2008–2009).
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedGoogle Scholar
- Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714–26.PubMedGoogle Scholar
- Florio T, Barbieri F. The status of the art of human malignant glioma management: the promising role of targeting tumor-initiating cells. Drug Discov Today. 2012;17(19–20):1103–10.PubMedGoogle Scholar
- Bao B, Ahmad A, Azmi AS, Ali S, Sarkar FH. Overview of cancer stem cells (CSCs) and mechanisms of their regulation: implications for cancer therapy. Curr Protoc Pharmacol. 2013;Chapter 14:14–25.Google Scholar
- Owens TW, Naylor MJ. Breast cancer stem cells. Front Physiol. 2013;4:225.PubMedPubMed CentralGoogle Scholar
- Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100(7):3983–8.PubMedPubMed CentralGoogle Scholar
- Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 2008;10(2):R25.PubMedPubMed CentralGoogle Scholar
- Manuel Iglesias J, Beloqui I, Garcia-Garcia F, Leis O, Vazquez-Martin A, Eguiara A, et al. Mammosphere formation in breast carcinoma cell lines depends upon expression of E-cadherin. PLoS One. 2013;8(10):e77281.PubMedPubMed CentralGoogle Scholar
- Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005;65(13):5506–11.PubMedGoogle Scholar
- Grimshaw MJ, Cooper L, Papazisis K, Coleman JA, Bohnenkamp HR, Chiapero-Stanke L, et al. Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells. Breast Cancer Res. 2008;10(3):R52.PubMedPubMed CentralGoogle Scholar
- Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 2006;9(5):391–403.PubMedGoogle Scholar
- Harrison H, Farnie G, Brennan KR, Clarke RB. Breast cancer stem cells: something out of notching? Cancer Res. 2010;70(22):8973–6.PubMedGoogle Scholar
- Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003;17(10):1253–70.PubMedPubMed CentralGoogle Scholar
- Farnie G, Clarke RB. Mammary stem cells and breast cancer–role of Notch signalling. Stem Cell Rev. 2007;3(2):169–75.PubMedGoogle Scholar
- Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer. 2008;8(2):147–56.PubMedGoogle Scholar
- Rowell JL, McCarthy DO, Alvarez CE. Dog models of naturally occurring cancer. Trends Mol Med. 2011;17(7):380–8.PubMedPubMed CentralGoogle Scholar
- Klopfleisch R, Lenze D, Hummel M, Gruber AD. Metastatic canine mammary carcinomas can be identified by a gene expression profile that partly overlaps with human breast cancer profiles. BMC Cancer. 2010;10:618.PubMedPubMed CentralGoogle Scholar
- Pang LY, Argyle DJ. Using naturally occurring tumours in dogs and cats to study telomerase and cancer stem cell biology. Biochim Biophys Acta. 2009;1792(4):380–91.PubMedGoogle Scholar
- Uva P, Aurisicchio L, Watters J, Loboda A, Kulkarni A, Castle J, et al. Comparative expression pathway analysis of human and canine mammary tumors. BMC Genomics. 2009;10:135.PubMedPubMed CentralGoogle Scholar
- Rivera P, von Euler H. Molecular biological aspects on canine and human mammary tumors. Vet Pathol. 2011;48(1):132–46.PubMedGoogle Scholar
- Pinho SS, Carvalho S, Cabral J, Reis CA, Gartner F. Canine tumors: a spontaneous animal model of human carcinogenesis. Transl Res. 2012;159(3):165–72.PubMedGoogle Scholar
- Queiroga FL, Raposo T, Carvalho MI, Prada J, Pires I. Canine mammary tumours as a model to study human breast cancer: most recent findings. In Vivo. 2011;25(3):455–65.PubMedGoogle Scholar
- Klopfleisch R, Klose P, Weise C, Bondzio A, Multhaup G, Einspanier R, et al. Proteome of metastatic canine mammary carcinomas: similarities to and differences from human breast cancer. J Proteome Res. 2010;9(12):6380–91.PubMedGoogle Scholar
- de Las Mulas JM, Millan Y, Dios R. A prospective analysis of immunohistochemically determined estrogen receptor alpha and progesterone receptor expression and host and tumor factors as predictors of disease-free period in mammary tumors of the dog. Vet Pathol. 2005;42(2):200–12.PubMedGoogle Scholar
- Pena L, Gama A, Goldschmidt MH, Abadie J, Benazzi C, Castagnaro M, et al. Canine mammary tumors: a review and consensus of standard guidelines on epithelial and myoepithelial phenotype markers, HER2, and hormone receptor assessment using immunohistochemistry. Vet Pathol. 2014;51(1):127–45.PubMedGoogle Scholar
- Kim NH, Lim HY, Im KS, Kim JH, Sur JH. Identification of triple-negative and basal-like canine mammary carcinomas using four basal markers. J Comp Pathol. 2013;148(4):298–306.PubMedGoogle Scholar
- Wilson H, Huelsmeyer M, Chun R, Young KM, Friedrichs K, Argyle DJ. Isolation and characterisation of cancer stem cells from canine osteosarcoma. Vet J. 2008;175(1):69–75.PubMedGoogle Scholar
- Pang LY, Gatenby EL, Kamida A, Whitelaw BA, Hupp TR, Argyle DJ. Global gene expression analysis of canine osteosarcoma stem cells reveals a novel role for COX-2 in tumour initiation. PLoS One. 2014;9(1):e83144.PubMedPubMed CentralGoogle Scholar
- Stoica G, Lungu G, Martini-Stoica H, Waghela S, Levine J, Smith 3rd R. Identification of cancer stem cells in dog glioblastoma. Vet Pathol. 2009;46(3):391–406.PubMedGoogle Scholar
- Imren S, Zhang XB, Humphries RK, Kiem HP. Insights into leukemia-initiating cell frequency and self-renewal from a novel canine model of leukemia. Exp Hematol. 2011;39(1):124–32.PubMedGoogle Scholar
- Michishita M, Ezaki S, Ogihara K, Naya Y, Azakami D, Nakagawa T, et al. Identification of tumor-initiating cells in a canine hepatocellular carcinoma cell line. Res Vet Sci. 2014;96(2):315–22.PubMedGoogle Scholar
- Barbieri F, Wurth R, Ratto A, Campanella C, Vito G, Thellung S, et al. Isolation of stem-like cells from spontaneous feline mammary carcinomas: phenotypic characterization and tumorigenic potential. Exp Cell Res. 2012;318(7):847–60.PubMedGoogle Scholar
- Ferletta M, Grawe J, Hellmen E. Canine mammary tumors contain cancer stem-like cells and form spheroids with an embryonic stem cell signature. Int J Dev Biol. 2011;55(7–9):791–9.PubMedGoogle Scholar
- Pang LY, Cervantes-Arias A, Else RW, Argyle DJ. Canine mammary cancer stem cells are radio- and chemo- resistant and exhibit an epithelial-mesenchymal transition phenotype. Cancers (Basel). 2011;3(2):1744–62.Google Scholar
- Michishita M, Akiyoshi R, Suemizu H, Nakagawa T, Sasaki N, Takemitsu H, et al. Aldehyde dehydrogenase activity in cancer stem cells from canine mammary carcinoma cell lines. Vet J. 2012;193(2):508–13.PubMedGoogle Scholar
- Cocola C, Anastasi P, Astigiano S, Piscitelli E, Pelucchi P, Vilardo L, et al. Isolation of canine mammary cells with stem cell properties and tumour-initiating potential. Reprod Domest Anim. 2009;44 Suppl 2:214–7.PubMedGoogle Scholar
- Magalhaes GM, Terra EM, de Oliveira VR, de Barros BM, Moreira PR, Rosolem MC, et al. Immunodetection of cells with a CD44+/CD24- phenotype in canine mammary neoplasms. BMC Vet Res. 2013;9:205.PubMedPubMed CentralGoogle Scholar
- Blacking TM, Waterfall M, Argyle DJ. CD44 is associated with proliferation, rather than a specific cancer stem cell population, in cultured canine cancer cells. Vet Immunol Immunopathol. 2011;141(1–2):46–57.PubMedGoogle Scholar
- Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334(9):574–9.PubMedGoogle Scholar
- Pollak M. Potential applications for biguanides in oncology. J Clin Invest. 2013;123(9):3693–700.PubMedPubMed CentralGoogle Scholar
- Quinn BJ, Kitagawa H, Memmott RM, Gills JJ, Dennis PA. Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metab. 2013;24(9):469–80.PubMedGoogle Scholar
- Kourelis TV, Siegel RD. Metformin and cancer: new applications for an old drug. Med Oncol. 2012;29(2):1314–27.PubMedGoogle Scholar
- Pernicova I, Korbonits M. Metformin–mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 2014;10(3):143–56.PubMedGoogle Scholar
- Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle. 2009;8(13):2031–40.PubMedGoogle Scholar
- Vazquez-Martin A, Oliveras-Ferraros C, Cufi S, Del Barco S, Martin-Castillo B, Lopez-Bonet E, et al. The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells. Oncol Rep. 2011;25(1):135–40.PubMedGoogle Scholar
- Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006;66(21):10269–73.PubMedGoogle Scholar
- Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle. 2009;8(6):909–15.PubMedGoogle Scholar
- Del Barco S, Vazquez-Martin A, Cufi S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J, et al. Metformin: multi-faceted protection against cancer. Oncotarget. 2011;2(12):896–917.PubMedPubMed CentralGoogle Scholar
- Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009;69(19):7507–11.PubMedPubMed CentralGoogle Scholar
- Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle. 2009;8(1):88–96.PubMedGoogle Scholar
- Vazquez-Martin A, Oliveras-Ferraros C, Del Barco S, Martin-Castillo B, Menendez JA. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Res Treat. 2011;126(2):355–64.PubMedGoogle Scholar
- Misdorp W, Else RW, Hellmén E, Lipscomb TP. Histological Classification of Mammary Tumors of the Dog and the Cat, vol. VII. In: Armed Forces Institute of Pathology in cooperation with the American Registry of Pathology and the World Health Organization Collaborating Center for Worldwide Reference on Comparative Oncology. 2nd ed. 1999.Google Scholar
- Misdorp W. Tumors of the mammary gland. In: Ames MD, editor. Tumors in Domestic Animals. 4th ed. Iowa, USA: Iowa State Press; 2002. p. 575–607.Google Scholar
- Ferrari A, Petterino C, Ratto A, Campanella C, Wurth R, Thellung S, et al. CXCR4 expression in feline mammary carcinoma cells: evidence of a proliferative role for the SDF-1/CXCR4 axis. BMC Vet Res. 2012;8:27.PubMedPubMed CentralGoogle Scholar
- Rozemuller H, Prins HJ, Naaijkens B, Staal J, Buhring HJ, Martens AC. Prospective isolation of mesenchymal stem cells from multiple mammalian species using cross-reacting anti-human monoclonal antibodies. Stem Cells Dev. 2010;19(12):1911–21.PubMedGoogle Scholar
- Singer J, Weichselbaumer M, Stockner T, Mechtcheriakova D, Sobanov Y, Bajna E, et al. Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting. Mol Immunol. 2012;50(4):200–9.PubMedPubMed CentralGoogle Scholar
- Ratto A, Petterino C, Florio T, Barbieri F. Goat anti-human GM-CSF recognizes canine GM-CSF. Vet Clin Pathol Am Soc Vet Clin Pathol. 2012;41(1):3–4.Google Scholar
- Griffero F, Daga A, Marubbi D, Capra MC, Melotti A, Pattarozzi A, et al. Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors. J Biol Chem. 2009;284(11):7138–48.PubMedPubMed CentralGoogle Scholar
- Bajetto A, Porcile C, Pattarozzi A, Scotti L, Aceto A, Daga A, et al. Differential role of EGF and BFGF in human GBM-TIC proliferation: relationship to EGFR-tyrosine kinase inhibitor sensibility. J Biol Regul Homeost Agents. 2013;27(1):143–54.PubMedGoogle Scholar
- Carra E, Barbieri F, Marubbi D, Pattarozzi A, Favoni RE, Florio T, et al. Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures. Cell Cycle. 2013;12(3):491–500.PubMedPubMed CentralGoogle Scholar
- Shen F, Chu S, Bence AK, Bailey B, Xue X, Erickson PA, et al. Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J Pharmacol Exp Ther. 2008;324(1):95–102.PubMedGoogle Scholar
- Wanjari MM, There AW, Tajne MR, Chopde CT, Umathe SN. Rapid and Simple RPHPLC Method for the Estimation of Metformin in Rat Plasma. Indian J Pharm Sci. 2008;70(2):198–202.PubMedPubMed CentralGoogle Scholar
- Welsh AW, Lannin DR, Young GS, Sherman ME, Figueroa JD, Henry NL, et al. Cytoplasmic estrogen receptor in breast cancer. Clin Cancer Res. 2012;18(1):118–26.PubMedGoogle Scholar
- Beck B, Blanpain C. Unravelling cancer stem cell potential. Nat Rev Cancer. 2013;13(10):727–38.PubMedGoogle Scholar
- Wurth R, Barbieri F, Florio T. New molecules and old drugs as emerging approaches to selectively target human glioblastoma cancer stem cells. BioMed Res Int. 2014;2014(Article ID 126586):Article ID 126586.Google Scholar
- Wurth R, Pattarozzi A, Gatti M, Bajetto A, Corsaro A, Parodi A, et al. Metformin selectively affects human glioblastoma tumor-initiating cell viability: a role for metformin-induced inhibition of Akt. Cell Cycle. 2013;12(1):145–56.PubMedPubMed CentralGoogle Scholar
- Kung AL. Practices and pitfalls of mouse cancer models in drug discovery. Adv Cancer Res. 2007;96:191–212.PubMedGoogle Scholar
- Paoloni M, Webb C, Mazcko C, Cherba D, Hendricks W, Lana S, et al. Prospective molecular profiling of canine cancers provides a clinically relevant comparative model for evaluating personalized medicine (PMed) trials. PLoS One. 2014;9(3):e90028.PubMedPubMed CentralGoogle Scholar
- Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1(5):555–67.PubMedPubMed CentralGoogle Scholar
- Sarrio D, Franklin CK, Mackay A, Reis-Filho JS, Isacke CM. Epithelial and mesenchymal subpopulations within normal basal breast cell lines exhibit distinct stem cell/progenitor properties. Stem Cells. 2012;30(2):292–303.PubMedGoogle Scholar
- Liu Y, Nenutil R, Appleyard MV, Murray K, Boylan M, Thompson AM, et al. Lack of correlation of stem cell markers in breast cancer stem cells. Br J Cancer. 2014;110(8):2063–71.PubMedPubMed CentralGoogle Scholar
- O'Connor ML, Xiang D, Shigdar S, Macdonald J, Li Y, Wang T, et al. Cancer stem cells: a contentious hypothesis now moving forward. Cancer Lett. 2014;344(2):180–7.PubMedGoogle Scholar
- Marangoni E, Lecomte N, Durand L, de Pinieux G, Decaudin D, Chomienne C, et al. CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts. Br J Cancer. 2009;100(6):918–22.PubMedPubMed CentralGoogle Scholar
- Pham PV, Phan NL, Nguyen NT, Truong NH, Duong TT, Le DV, et al. Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy. J Transl Med. 2011;9:209.PubMedPubMed CentralGoogle Scholar
- Van Phuc P, Nhan PL, Nhung TH, Tam NT, Hoang NM, Tue VG, et al. Downregulation of CD44 reduces doxorubicin resistance of CD44CD24 breast cancer cells. Onco Targets Ther. 2011;4:71–8.PubMedPubMed CentralGoogle Scholar
- Rich JN, Eyler CE. Cancer stem cells in brain tumor biology. Cold Spring Harb Symp Quant Biol. 2008;73:411–20.PubMedGoogle Scholar
- Carvalho MI, Guimaraes MJ, Pires I, Prada J, Silva-Carvalho R, Lopes C, et al. EGFR and microvessel density in canine malignant mammary tumours. Res Vet Sci. 2013;95(3):1094–9.PubMedGoogle Scholar
- Pattarozzi A, Gatti M, Barbieri F, Wurth R, Porcile C, Lunardi G, et al. 17beta-estradiol promotes breast cancer cell proliferation-inducing stromal cell-derived factor-1-mediated epidermal growth factor receptor transactivation: reversal by gefitinib pretreatment. Mol Pharmacol. 2008;73(1):191–202.PubMedGoogle Scholar
- Ablett MP, O'Brien CS, Sims AH, Farnie G, Clarke RB. A differential role for CXCR4 in the regulation of normal versus malignant breast stem cell activity. Oncotarget. 2014;5(3):599–612.PubMedGoogle Scholar
- Lehmann C, Jobs G, Thomas M, Burtscher H, Kubbies M. Established breast cancer stem cell markers do not correlate with in vivo tumorigenicity of tumor-initiating cells. Int J Oncol. 2012;41(6):1932–42.PubMedPubMed CentralGoogle Scholar
- Calvet CY, Andre FM, Mir LM. The culture of cancer cell lines as tumorspheres does not systematically result in cancer stem cell enrichment. PLoS One. 2014;9(2):e89644.PubMedPubMed CentralGoogle Scholar
- Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell. 2012;21(3):283–96.PubMedPubMed CentralGoogle Scholar
- Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008;100(9):672–9.PubMedGoogle Scholar
- Gou S, Cui P, Li X, Shi P, Liu T, Wang C. Low concentrations of metformin selectively inhibit CD133(+) cell proliferation in pancreatic cancer and have anticancer action. PLoS One. 2013;8(5):e63969.PubMedPubMed CentralGoogle Scholar
- Saito T, Chiba T, Yuki K, Zen Y, Oshima M, Koide S, et al. Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells. PLoS One. 2013;8(7):e70010.PubMedPubMed CentralGoogle Scholar
- Iliopoulos D, Hirsch HA, Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res. 2011;71(9):3196–201.PubMedPubMed CentralGoogle Scholar
- Cufi S, Corominas-Faja B, Vazquez-Martin A, Oliveras-Ferraros C, Dorca J, Bosch-Barrera J, et al. Metformin-induced preferential killing of breast cancer initiating CD44 + CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts. Oncotarget. 2012;3(4):395–8.PubMedPubMed CentralGoogle Scholar
- Anisimov VN. [Effect of buformin and diphenylhydantoin on the life span, estrous function and spontaneous tumor incidence in rats]. Vopr Onkol. 1980;26(6):42–8.PubMedGoogle Scholar
- Dil'man VM, Anisimov VN. [Increase in longevity and a decrease in the frequency of tumors in C3H/Sn mice under the influence of fenformin and diphenin]. Dokl Akad Nauk SSSR. 1979;245(3):753–7.PubMedGoogle Scholar
- Dil'man VM, Bershtein LM, Zabezhinskii MA, Aleksandrov VA. [Effect of phenformin on mammary gland tumor induction in rats]. Vopr Onkol. 1974;20(9):94–8.PubMedGoogle Scholar
- Emami Riedmaier A, Fisel P, Nies AT, Schaeffeler E, Schwab M. Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects. Trends Pharmacol Sci. 2013;34(2):126–35.PubMedGoogle Scholar
- Thompson AM. Molecular pathways: preclinical models and clinical trials with metformin in breast cancer. Clin Cancer Res. 2014;20(10):2508–15.PubMedGoogle Scholar
- Gritti M, Wurth R, Angelini M, Barbieri F, Peretti M, Pizzi E, et al. Metformin repositioning as antitumoral agent: selective antiproliferative effects in human glioblastoma stem cells, via inhibition of CLIC1-mediated ion current. Oncotarget. 2014;5(22):11252–68.PubMedPubMed CentralGoogle Scholar
- Liu S, Wicha MS. Targeting breast cancer stem cells. J Clin Oncol. 2010;28(25):4006–12.PubMedPubMed CentralGoogle Scholar
- Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell. 2011;146(4):633–44.PubMedGoogle Scholar
- Chen G, Xu S, Renko K, Derwahl M. Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. J Clin Endocrinol Metab. 2012;97(4):E510–20.PubMedGoogle Scholar
- Rocha GZ, Dias MM, Ropelle ER, Osorio-Costa F, Rossato FA, Vercesi AE, et al. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth. Clin Cancer Res. 2011;17(12):3993–4005.PubMedGoogle Scholar
- Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle. 2010;9(6):1057–64.PubMedGoogle Scholar
- Wilcock C, Bailey CJ. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica. 1994;24(1):49–57.PubMedGoogle Scholar
- Fendt SM, Bell EL, Keibler MA, Davidson SM, Wirth GJ, Fiske B, et al. Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res. 2013;73(14):4429–38.PubMedPubMed CentralGoogle Scholar
- Menendez JA, Oliveras-Ferraros C, Cufi S, Corominas-Faja B, Joven J, Martin-Castillo B, et al. Metformin is synthetically lethal with glucose withdrawal in cancer cells. Cell Cycle. 2012;11(15):2782–92.PubMedGoogle Scholar
- Deng XS, Wang S, Deng A, Liu B, Edgerton SM, Lind SE, et al. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle. 2012;11(2):367–76.PubMedGoogle Scholar
- Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22(3):659–61.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.